Business
/C O R R E C T I O N -- Hoth Therapeutics, Inc./
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company developing innovative therapies for unmet medical needs, today announced compelling preclinical data for HT-KIT, its proprietary antisense oligonucleotide (ASO) therapeutic designed to target and silence aberrant KIT gene expression—implicated in a variety of rare, treatment-resistant cancers.
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"In the news release, Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers, issued 12-May-2025 by Hoth Therapeutics, Inc. over PR Newswire, we are advised by the company that the 3rd bullet section, 2nd bullet should read "Significant inhibition of tumor growth". The complete, corrected release follows:","length":406,"tagName":"p"},{"type":"heading","content":"Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers","length":145,"tagName":"h3","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis. ","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"Treatment shows potent downregulation of oncogenic KIT mutations with no observed systemic toxicity. ","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"IND filing expected early 2026, opening pathway to first-in-human trials. ","length":73,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":283,"olType":false},{"type":"text","content":"Preclinical Milestones:","length":23,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Over 80% reduction in KIT expression in vitro using cancer cell lines harboring activating KIT mutations.","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"Significant inhibition of tumor growth in GIST and mast cell tumor animal models following systemic administration of HT-KIT.","length":125,"tagName":"p"}]},{"val":[{"type":"text","content":"No observable off-target toxicity in liver, kidney, or bone marrow, suggesting a favorable safety profile.","length":106,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":336,"olType":false},{"type":"text","content":"NEW YORK, May 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company developing innovative therapies for unmet medical needs, today announced compelling preclinical data for HT-KIT, its proprietary antisense oligonucleotide (ASO) therapeutic designed to target and silence aberrant KIT gene expression—implicated in a variety of rare, treatment-resistant cancers....